Last reviewed · How we verify
Vi Polysaccharide
At a glance
| Generic name | Vi Polysaccharide |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vellore Typhoid Vaccine Impact Trial (PHASE4)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women (NA)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Inflammatory Challenge and Fear (PHASE1)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vi Polysaccharide CI brief — competitive landscape report
- Vi Polysaccharide updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI